Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX148 + PLD + Pembrolizumab in Platinum-resistant Ovarian Cancer
NCT05467670Phase 2Active, not recruiting
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of evorpacept in ovarian cancer. Started Mar 2023; status: active, not recruiting.
02
Drugs
evorpacept
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05467670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467670.